Jump to content

Acetohexamide

From Wikipedia, the free encyclopedia
(Redirected from Gamadiabet)
Acetohexamide
Clinical data
Trade namesDymelor
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa602021
ATC code
Pharmacokinetic data
Protein binding90%
Identifiers
  • 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.012.301 Edit this at Wikidata
Chemical and physical data
FormulaC15H20N2O4S
Molar mass324.40 g·mol−1
3D model (JSmol)
Melting point188 to 190 °C (370 to 374 °F)
  • O=C(NC1CCCCC1)NS(=O)(=O)c2ccc(C(=O)C)cc2
  • InChI=1S/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19) checkY
  • Key:VGZSUPCWNCWDAN-UHFFFAOYSA-N checkY
  (verify)

Acetohexamide (trade name Dymelor) is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone.[1]

Mechanism of action

[edit]

Acetohexamide binds to an ATP-sensitive K+ (KATP) channel on the cell membrane of pancreatic beta cells. This inhibits the outflux of potassium, which causes the membrane potential to become more positive. This depolarization in turn opens voltage-gated calcium channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of insulin.[2]

Risks

[edit]

Sulfonylureas, especially first-generation sulfonylureas such as Acetohexamide, can cause severe hypoglycemia and increase the risk of adverse cardiovascular events. [3][4]

References

[edit]
  1. ^ Montgomery DA (October 1964). "Current Therapeutics. CCII. Acetohexamide". The Practitioner. 193: 555–60. PMID 14216839.
  2. ^ "Acetohexamide". DrugBank.
  3. ^ "www.accessdata.fda.gov" (PDF).
  4. ^ "Acetohexamide". Medline Plus. Archived from the original on 11 September 2005.